Genetic allergen modification in the development of novel approaches to specific immunotherapy
Authors:
- 21 October 2009
- journal article
- review article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 39 (11) , 1635-1642
Abstract
In the recent past, multiple allergens from relevant allergen sources have been cloned, sequenced and produced as recombinant proteins. The availability of recombinant allergens with immunological characteristics similar to their natural counterparts has improved the diagnosis of allergic disorders and increased our knowledge of the biochemical, structural and immunological characteristics of proteins with allergenic potential. Moreover, the use of defined recombinant proteins as vaccines substituting currently used total protein extracts from allergen sources may improve specific immunotherapy (SIT) of Type I allergy. In addition to producing well-defined batches of wild-type allergens, the recombinant technology offers the possibility to easily and selectively modify their properties or functions. Diverse modifications of allergens can be genetically engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused with proteins that promote immune responses, which counterregulate the disease-eliciting T-helper type 2-dominated immune response in allergic individuals and may therefore, improve the efficacy of SIT. This review will introduce different concepts of allergen modification using genetic engineering to improve vaccines for SIT of Type I allergy.Keywords
This publication has 79 references indexed in Scilit:
- Natural Self-Assembly of Allergen-S-Layer Fusion Proteins Is No Prerequisite for Reduced Allergenicity and T Cell Stimulatory CapacityInternational Archives of Allergy and Immunology, 2009
- Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapyAllergy, 2008
- In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposureJournal of Experimental Medicine, 2008
- Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesClinical & Experimental Allergy, 2008
- A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6Biological Chemistry, 2008
- Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1–related food allergensJournal of Allergy and Clinical Immunology, 2005
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Activating and inhibitory signaling in mast cells: New opportunities for therapeutic intervention?Journal of Allergy and Clinical Immunology, 2000
- Preserved epitope‐specific T cell activation by recombinant Bet v 1‐MBP fusion proteinsClinical & Experimental Allergy, 1998
- Preparation and Properties of ‘Allergoids’ Derived from Native Pollen Allergens by Mild Formalin TreatmentInternational Archives of Allergy and Immunology, 1971